CA3202029A1 - Pharmaceutical formulation - Google Patents
Pharmaceutical formulationInfo
- Publication number
- CA3202029A1 CA3202029A1 CA3202029A CA3202029A CA3202029A1 CA 3202029 A1 CA3202029 A1 CA 3202029A1 CA 3202029 A CA3202029 A CA 3202029A CA 3202029 A CA3202029 A CA 3202029A CA 3202029 A1 CA3202029 A1 CA 3202029A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- semi
- pharmaceutical formulation
- solid
- polyethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2100526.9A GB202100526D0 (en) | 2021-01-15 | 2021-01-15 | Pharmaceutical formulation |
| GB2100526.9 | 2021-01-15 | ||
| PCT/GB2022/050083 WO2022153062A1 (en) | 2021-01-15 | 2022-01-14 | Pharmaceutical formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3202029A1 true CA3202029A1 (en) | 2022-07-21 |
Family
ID=74678956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3202029A Pending CA3202029A1 (en) | 2021-01-15 | 2022-01-14 | Pharmaceutical formulation |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240082244A1 (https=) |
| EP (1) | EP4277606A1 (https=) |
| JP (1) | JP2024505630A (https=) |
| KR (1) | KR20230133285A (https=) |
| CN (1) | CN116710077A (https=) |
| AU (1) | AU2022208241A1 (https=) |
| CA (1) | CA3202029A1 (https=) |
| GB (1) | GB202100526D0 (https=) |
| MX (1) | MX2023008406A (https=) |
| WO (1) | WO2022153062A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220023266A1 (en) | 2018-12-07 | 2022-01-27 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
| JP7623365B2 (ja) | 2019-09-27 | 2025-01-28 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよび使用方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA845180B (en) * | 1983-07-07 | 1986-02-26 | American Home Prod | Pharmaceutical composition containing a liquid lubricant |
| US9783550B2 (en) * | 2013-05-14 | 2017-10-10 | The Board Of Regents Of The University Of Texas System | Highly potent inhibitors of porcupine |
| KR102525131B1 (ko) * | 2014-10-08 | 2023-04-24 | 레드엑스 파마 피엘씨 | Wnt 신호 경로의 억제제로서의 N-피리디닐 아세트아미드 유도체 |
| CN111971063A (zh) * | 2018-04-06 | 2020-11-20 | 4阵营疗法公司 | 通过靶向调节基因信号传导网络治疗疾病 |
-
2021
- 2021-01-15 GB GBGB2100526.9A patent/GB202100526D0/en not_active Ceased
-
2022
- 2022-01-14 CA CA3202029A patent/CA3202029A1/en active Pending
- 2022-01-14 WO PCT/GB2022/050083 patent/WO2022153062A1/en not_active Ceased
- 2022-01-14 JP JP2023542980A patent/JP2024505630A/ja active Pending
- 2022-01-14 EP EP22701416.4A patent/EP4277606A1/en active Pending
- 2022-01-14 CN CN202280010206.5A patent/CN116710077A/zh active Pending
- 2022-01-14 MX MX2023008406A patent/MX2023008406A/es unknown
- 2022-01-14 AU AU2022208241A patent/AU2022208241A1/en active Pending
- 2022-01-14 US US18/271,913 patent/US20240082244A1/en active Pending
- 2022-01-14 KR KR1020237023066A patent/KR20230133285A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022208241A9 (en) | 2025-01-09 |
| JP2024505630A (ja) | 2024-02-07 |
| GB202100526D0 (en) | 2021-03-03 |
| MX2023008406A (es) | 2023-08-03 |
| EP4277606A1 (en) | 2023-11-22 |
| AU2022208241A1 (en) | 2023-07-06 |
| US20240082244A1 (en) | 2024-03-14 |
| CN116710077A (zh) | 2023-09-05 |
| WO2022153062A1 (en) | 2022-07-21 |
| KR20230133285A (ko) | 2023-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU762926B2 (en) | Methods and compositions for delivery of taxanes | |
| TWI233355B (en) | Oral formulations for anti-tumor compounds | |
| US20220265682A1 (en) | Drug composition containing abiraterone acetate, and preparation method therefor and application thereof | |
| US20030220391A1 (en) | Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability | |
| JP2016172745A (ja) | ペプチドの組成物及びその調製方法 | |
| CN105055303A (zh) | 含酸的脂质制剂 | |
| CA3202029A1 (en) | Pharmaceutical formulation | |
| KR20100016048A (ko) | 타미바로텐 캡슐제 | |
| Hong et al. | Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation | |
| CN101780037A (zh) | 双嘧达莫自乳化给药系统及其制备方法 | |
| CN104473873B (zh) | 一种卡巴他赛长循环脂质体注射剂及其制备方法 | |
| JP2021523195A (ja) | Ｈｃ−１１１９製剤及びその製造方法と使用 | |
| EP4259111B1 (en) | PHARMACEUTICAL COMPOSITIONS COMPRISING A CANNABINOID AGONIST | |
| WO2004073692A1 (ja) | 難水溶性薬物のハードカプセル剤 | |
| CN109172520A (zh) | 一种紫杉烷类衍生物tm-2胶束注射液及其制备方法与应用 | |
| JP2017518980A (ja) | タペンタドールを含む、改変防止即時放出カプセル製剤 | |
| KR101739731B1 (ko) | 유당불내성 환자에게 투여가 가능하며, 복용편의성이 향상된 게피티니브를 함유하는 약제학적 조성물 | |
| US20230090337A1 (en) | Pharmaceutical formulations comprising 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1 -yl)-2-(1,3-dimethyl-1 hpyrazol-4-yl)-3h- imidazo[4,5-b]pyridine | |
| KR101819310B1 (ko) | 사이클로스포린을 포함하는 약학 조성물 | |
| Sunil et al. | Development and evaluation of a chronotherapeutic drug delivery system of torsemide | |
| KR20240053626A (ko) | 강화된 sn-38 용해성 및 경구 흡수성을 갖는 제형 | |
| KR100679925B1 (ko) | 신규한 ５―플루오로우라실 좌제 조성물 | |
| KR20190038027A (ko) | 아세트아미노펜, 및 트라마돌 또는 이의 약학적 허용 가능한 염을 포함하는 연질캡슐 조성물 | |
| KR20170078972A (ko) | 사이클로스포린을 포함하는 약학 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250106 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250106 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250106 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251223 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260107 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260107 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260107 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260218 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260218 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260218 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260218 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260218 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260218 |